Seaport Global Securities restated their buy rating on shares of Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) in a research note published on Friday, October 6th, MarketBeat Ratings reports. The firm currently has a $13.00 target price on the stock.
A number of other brokerages have also commented on RNN. HC Wainwright set a $20.00 target price on Rexahn Pharmaceuticals and gave the company a buy rating in a research report on Monday, September 11th. Zacks Investment Research downgraded Rexahn Pharmaceuticals from a hold rating to a sell rating in a report on Tuesday, July 18th. Rodman & Renshaw reissued a buy rating and issued a $19.50 price target on shares of Rexahn Pharmaceuticals in a report on Friday, June 9th. Finally, Ifs Securities reaffirmed an outperform rating on shares of Rexahn Pharmaceuticals in a research note on Monday, August 7th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus target price of $13.85.
Rexahn Pharmaceuticals (NYSEMKT:RNN) opened at 2.17 on Friday. The company’s market cap is $61.76 million. Rexahn Pharmaceuticals has a 52 week low of $0.13 and a 52 week high of $4.74. The stock has a 50 day moving average of $2.49 and a 200 day moving average of $2.32.
TRADEMARK VIOLATION NOTICE: This story was published by BBNS and is the sole property of of BBNS. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://baseballnewssource.com/markets/rexahn-pharmaceuticals-inc-rnn-now-covered-by-analysts-at-seaport-global-securities/1689986.html.
A number of hedge funds and other institutional investors have recently bought and sold shares of RNN. Sabby Management LLC acquired a new position in Rexahn Pharmaceuticals in the 2nd quarter valued at $706,000. Susquehanna International Group LLP purchased a new stake in Rexahn Pharmaceuticals in the 2nd quarter valued at $2,905,000. Finally, Renaissance Technologies LLC grew its holdings in Rexahn Pharmaceuticals by 17.6% in the 1st quarter. Renaissance Technologies LLC now owns 5,758,391 shares of the company’s stock valued at $2,937,000 after buying an additional 862,000 shares in the last quarter.
Rexahn Pharmaceuticals Company Profile
Rexahn Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.
Receive News & Ratings for Rexahn Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.